How Can I Tell If a Pharmacy or Medication Is FDA-Approved?

How to Check If a Medication Is FDA-Approved

The fastest way to confirm FDA approval is the agency's own public databases. Two free tools give you a definitive answer in under a minute. If a drug does not appear in either database, it has not received FDA approval for any indication in the United States.

The Drugs@FDA Database

The Drugs@FDA database is searchable by brand name, active ingredient, or application number. Each listing shows the approval date, approved indications, current labeling, and any post-market safety communications. For example, searching "semaglutide" returns entries for Ozempic (approved December 2017 for type 2 diabetes), Wegovy (approved June 2021 for chronic weight management), and Rybelsus (approved September 2019 for type 2 diabetes) [1]. The database updates within days of new approvals.

The FDA Orange Book

The Orange Book lists approved drug products with therapeutic equivalence evaluations. It is particularly useful when comparing brand-name drugs to their generic counterparts. Each product entry includes the active ingredient, dosage form, route of administration, strength, and the reference listed drug. The Orange Book is the standard pharmacists use to determine whether a generic can be substituted for a brand [2].

What "FDA-Approved" Actually Means

FDA approval means the agency reviewed clinical trial data showing a drug is safe and effective for its labeled indication. The process typically takes 10 to 15 years from initial compound discovery through Phase I, II, and III trials, then New Drug Application (NDA) or Biologics License Application (BLA) review. Approval does not mean a drug is risk-free. It means the FDA determined the benefits outweigh the risks for the approved population and indication [3].

A drug can be legally marketed in the U.S. Without full NDA approval in limited cases: drugs marketed before 1938 and certain over-the-counter monograph drugs. These exceptions are narrow. For prescription medications, including all GLP-1 receptor agonists, full FDA approval or Emergency Use Authorization is required.

How to Verify a Pharmacy Is Legitimate

A legitimate pharmacy follows federal and state laws, requires valid prescriptions, and employs licensed pharmacists. The verification process takes about five minutes using three publicly available tools.

State Board of Pharmacy Lookup

Every U.S. State maintains a board of pharmacy with a searchable license database. Enter the pharmacy's name or license number to confirm active status, disciplinary history, and whether the license covers retail, mail-order, or both. The pharmacy must hold a license in the state where the patient resides, not just the state where it physically operates [4]. Out-of-state mail-order pharmacies need a nonresident pharmacy license in the patient's state.

NABP Verification Programs

The National Association of Boards of Pharmacy runs two verification programs. The VIPPS (Verified Internet Pharmacy Practice Sites) program accredits online pharmacies that comply with all state and federal laws. The .pharmacy domain program provides verified domain names exclusively to legitimate pharmacies. NABP has reviewed over 11,000 internet pharmacy websites. Approximately 95% were found to be operating out of compliance with pharmacy laws and practice standards [5].

Red Flags That Signal an Illegitimate Pharmacy

Watch for these specific warning signs. A pharmacy that sells prescription drugs without requiring a prescription is operating illegally. Prices dramatically below market rates suggest counterfeit or diverted products. Absence of a licensed pharmacist available for consultation violates state pharmacy practice acts. No verifiable U.S. Street address or phone number is another disqualifying sign. Spam emails offering prescription medications are almost always tied to illegal operations [5].

Compounding Pharmacies and FDA Oversight

Compounding pharmacies occupy a distinct regulatory category. They do not sell FDA-approved finished products. Instead, they prepare customized medications based on individual prescriptions. This distinction matters significantly for patients considering compounded GLP-1 formulations.

503A vs. 503B Facilities

Section 503A of the Federal Food, Drug, and Cosmetic Act covers traditional compounding pharmacies. These prepare medications for individual patients based on specific prescriptions. They are primarily regulated by state boards of pharmacy. Section 503B covers outsourcing facilities, which can compound larger batches without patient-specific prescriptions. Outsourcing facilities must register with the FDA, report adverse events, and submit to FDA inspections [6].

How Compounding Applies to GLP-1 Medications

The FDA has placed semaglutide and tirzepatide on the drug shortage list at various points, which temporarily permitted compounding under section 503A and 503B. When the FDA removes a drug from the shortage list, compounding of that drug must cease within a defined wind-down period. In October 2024, the FDA removed tirzepatide from the shortage list, triggering significant regulatory changes for compounders [7]. The FDA issued warning letters to multiple compounding pharmacies for producing semaglutide products that did not meet quality standards or that made unapproved claims.

Verifying a Compounding Pharmacy

For 503B outsourcing facilities, the FDA's registered outsourcing facility list is searchable by facility name and state. For 503A pharmacies, check state board of pharmacy licensure and look for accreditation from the Pharmacy Compounding Accreditation Board (PCAB). PCAB accreditation requires compliance with United States Pharmacopeia (USP) chapters 795, 797, and 800 covering non-sterile compounding, sterile compounding, and hazardous drug handling, respectively [8].

Why Counterfeit and Substandard Medications Are Dangerous

The risk is not theoretical. The World Health Organization estimated in 2017 that approximately 10.5% of medical products in low- and middle-income countries were substandard or falsified [9]. In the U.S., the FDA's Office of Criminal Investigations opened over 200 cases related to illegal pharmaceutical activity in fiscal year 2023 alone.

Specific Risks with Counterfeit GLP-1 Medications

The FDA issued multiple alerts about counterfeit Ozempic pens found in the U.S. Drug supply chain in 2023 and 2024. These counterfeit pens contained unknown substances that could not be verified for sterility, identity, or potency [10]. Some tested samples contained no active semaglutide at all. Others contained incorrect doses that could cause hypoglycemia or ineffective treatment.

Health Consequences of Substandard Products

Substandard medications carry three primary clinical risks. Insufficient active ingredient leads to treatment failure, which in the case of GLP-1 therapy for type 2 diabetes could mean uncontrolled blood glucose and progressive beta-cell decline. Excessive active ingredient or contaminants can produce adverse effects ranging from injection site reactions to systemic toxicity. Lack of sterility in injectable products can cause infections including sepsis [10].

The FDA's BeSafeRx campaign specifically warns consumers that medications purchased from illegal online pharmacies may contain the wrong active ingredient, the wrong amount of active ingredient, or dangerous ingredients not listed on the label [5].

FDA-Approved GLP-1 Medications: A Complete List

Knowing which GLP-1 and GIP/GLP-1 medications have FDA approval helps patients distinguish legitimate products from unapproved alternatives.

Currently Approved GLP-1 Receptor Agonists

Semaglutide holds three separate approvals: Ozempic (injection, type 2 diabetes, approved 2017), Wegovy (injection, chronic weight management, approved 2021 with an expanded cardiovascular indication added in March 2024 based on the SELECT trial), and Rybelsus (oral tablet, type 2 diabetes, approved 2019) [1]. The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% compared to placebo in adults with overweight or obesity and established cardiovascular disease [11].

Liraglutide has two approved formulations: Victoza (type 2 diabetes, approved 2010) and Saxenda (chronic weight management, approved 2014). Dulaglutide (Trulicity) received approval for type 2 diabetes in 2014. Exenatide exists as both Byetta (twice-daily injection, approved 2005) and Bydureon BCise (once-weekly injection, approved 2012) [1].

Dual GIP/GLP-1 Agonists

Tirzepatide holds two approvals: Mounjaro (type 2 diabetes, approved May 2022) and Zepbound (chronic weight management, approved November 2023). In the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks versus 2.4% with placebo [12].

Medications Not FDA-Approved

Compounded semaglutide, compounded tirzepatide, semaglutide sublingual tablets (not the same as Rybelsus), and any "research-grade" GLP-1 peptides sold without a prescription are not FDA-approved products. Retatrutide, survodutide, orforglipron, and other pipeline GLP-1 medications remain investigational as of May 2026 [1].

How the Prescription Verification Process Works

Even with an FDA-approved medication from a licensed pharmacy, the prescription itself needs to originate from a legitimate provider-patient relationship.

Telehealth Prescribing Standards

The DEA and state medical boards set rules for telehealth prescribing. For non-controlled medications like GLP-1 receptor agonists, most states permit prescribing after a synchronous audio-video visit with a licensed provider. Some states allow asynchronous (questionnaire-based) prescribing for certain medication categories, though clinical guidelines from the American Medical Association recommend synchronous evaluation for weight management medications to allow proper assessment of BMI, comorbidities, and contraindications [13].

What a Legitimate Telehealth Provider Requires

A credible prescriber will verify your medical history, current medications, allergies, and contraindications before prescribing. They will order baseline labs (HbA1c, lipid panel, kidney function, thyroid function) or review recent results. They will discuss the black box warning for semaglutide and tirzepatide regarding thyroid C-cell tumors observed in rodent studies [14]. Any provider willing to prescribe without these steps raises concerns about quality of care.

Verifying Your Provider's License

The Federation of State Medical Boards maintains DocInfo.org, a free database that shows whether a physician holds an active, unrestricted license in the state where they are treating you. Nurse practitioners and physician assistants can be verified through their respective state licensing boards. The provider must be licensed in the state where the patient is physically located at the time of the consultation, regardless of where the provider is physically located [13].

What to Do If You Suspect a Counterfeit or Unapproved Product

If you believe you have received a counterfeit, unapproved, or substandard medication, three reporting channels exist.

FDA MedWatch Reporting

The FDA MedWatch program accepts voluntary reports from consumers and healthcare professionals about adverse events, product quality problems, and suspected counterfeit medications. Reports can be filed online, by phone (1-800-FDA-1088), or by mail. The FDA uses MedWatch data to identify safety signals and initiate enforcement actions [15].

State Board of Pharmacy Complaints

File a complaint with the state board of pharmacy where the pharmacy is licensed. State boards have authority to inspect, fine, suspend, or revoke pharmacy licenses. Most boards offer online complaint forms and investigate within 30 to 90 days.

Additional Steps

Stop taking the suspected product. Preserve the medication, packaging, and any receipts or shipping documentation. Contact your prescribing provider for an alternative supply from a verified pharmacy. If you experience adverse effects, seek medical attention and mention the suspected counterfeit product to your healthcare team.

The FDA's BeSafeRx program maintains an updated list of recommended resources at fda.gov/BeSafeRx, including links to NABP's pharmacy verification tools and state board lookup directories [5].